Kinex Pharmaceuticals
and its Korean partner Hanmi Pharmaceutical Co. Ltd. have executed an
agreement whereby Kinex is leading the development of its Orascovery
program in India.
Hanmi’s Orascovery technology allows intravenous
cancer drugs to be taken orally. It led to initiation of trials of the
widely-used cancer drug Paclitaxel, called Oraxol, currently in Phase II
clinical trials in Gastric Cancer patients in Korea, and Irinotecan
(Oratecan), which is used for Colon Cancer treatment. Getting access in China in 2013 and India in 2015 provides Kinex a
gateway to virtually all of the global market for Orascovery, with the
exception of Japan and the Koreas.
Kinex will assume all development responsibility in the licensed
territories. ZenRx has joined the effort to develop Oraxol and Oratecan
in the New Zealand and Australia territories, and PharmaEssentia of
Taiwan has joined the effort to develop Oraxol and Oratecan in Taiwan
and Singapore.
No comments:
Post a Comment